MACE-话题@MedSci

#MACE#

48篇内容 | 1632人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1575230, encodeId=a34d15e52307d, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=62, createdTime=2022-09-15, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575229, encodeId=b72815e522942, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, objectType=article, longId=726291, objectId=eddae262914c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eddae262914c, replyNumber=0, likeNumber=125, createdTime=2022-05-08, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eddae262914c, moduleTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eddae262914c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575228, encodeId=711a15e52289c, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关, objectType=article, longId=724839, objectId=0f64e24839a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f64e24839a9, replyNumber=0, likeNumber=85, createdTime=2022-04-24, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f64e24839a9, moduleTitle=DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f64e24839a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575227, encodeId=9c0a15e522796, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, objectType=article, longId=724127, objectId=b5ebe2412785, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5ebe2412785, replyNumber=0, likeNumber=90, createdTime=2022-04-14, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5ebe2412785, moduleTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5ebe2412785)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575226, encodeId=316a15e52261d, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？, objectType=article, longId=300781, objectId=d915300e8164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d915300e8164, replyNumber=0, likeNumber=111, createdTime=2022-03-16, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d915300e8164, moduleTitle=European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d915300e8164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575225, encodeId=653215e52252d, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, objectType=article, longId=219842, objectId=267d219842d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267d219842d5, replyNumber=0, likeNumber=69, createdTime=2021-11-07, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267d219842d5, moduleTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=267d219842d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575224, encodeId=aa2b15e52240e, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药, objectType=article, longId=218658, objectId=c75f218658a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75f218658a9, replyNumber=0, likeNumber=118, createdTime=2021-10-17, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75f218658a9, moduleTitle=Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c75f218658a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575223, encodeId=c96615e5223f3, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, objectType=article, longId=218421, objectId=20732184217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20732184217a, replyNumber=0, likeNumber=44, createdTime=2021-10-13, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20732184217a, moduleTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20732184217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575222, encodeId=9db115e5222ea, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响, objectType=article, longId=218238, objectId=779121823886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779121823886, replyNumber=0, likeNumber=67, createdTime=2021-10-10, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779121823886, moduleTitle=Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779121823886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575221, encodeId=7c6815e5221ed, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药, objectType=article, longId=217612, objectId=ab6b21e61271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6b21e61271, replyNumber=0, likeNumber=83, createdTime=2021-09-26, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6b21e61271, moduleTitle=Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6b21e61271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=心血管回顾性研究采用MACE作为结局哪些地方会被挑战 ?, objectType=article, longId=215014, objectId=119d21501478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119d21501478, replyNumber=0, likeNumber=62, createdTime=2021-07-31, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119d21501478, moduleTitle=心血管回顾性研究采用MACE作为结局哪些地方会被挑战 ?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119d21501478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575219, encodeId=377e15e521931, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益, objectType=article, longId=214526, objectId=60f3214526b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f3214526b7, replyNumber=0, likeNumber=88, createdTime=2021-07-22, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f3214526b7, moduleTitle=Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60f3214526b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575218, encodeId=7c6815e5218e1, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！, objectType=article, longId=213452, objectId=4a9121345224, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9121345224, replyNumber=0, likeNumber=72, createdTime=2021-06-30, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9121345224, moduleTitle=Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9121345224)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575217, encodeId=d46515e521792, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据, objectType=article, longId=207251, objectId=158620e25189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=158620e25189, replyNumber=0, likeNumber=120, createdTime=2021-02-20, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=158620e25189, moduleTitle=Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=158620e25189)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575216, encodeId=157f15e521659, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒, objectType=article, longId=205740, objectId=214b205e4021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=214b205e4021, replyNumber=0, likeNumber=88, createdTime=2021-01-16, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=214b205e4021, moduleTitle=ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=214b205e4021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575215, encodeId=9b2d15e521563, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Sirtex Medical和China Grand Pharmaceutical宣布SIR-Spheres Y-90树脂微球获得NMPA认可, objectType=article, longId=203881, objectId=7561203881be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7561203881be, replyNumber=0, likeNumber=77, createdTime=2020-12-01, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7561203881be, moduleTitle=Sirtex Medical和China Grand Pharmaceutical宣布SIR-Spheres Y-90树脂微球获得NMPA认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7561203881be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575214, encodeId=c02d15e5214e9, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, objectType=article, longId=202457, objectId=68f020245ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f020245ef3, replyNumber=0, likeNumber=103, createdTime=2020-10-26, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f020245ef3, moduleTitle=Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68f020245ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, objectType=article, longId=202450, objectId=e82920245051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82920245051, replyNumber=0, likeNumber=66, createdTime=2020-10-26, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82920245051, moduleTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e82920245051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575212, encodeId=99ea15e521275, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Mol. Pharmaceutics：加拿大科学家开发新方法，可将抗癌药物**输送到肿瘤, objectType=article, longId=197115, objectId=0a7519e1151f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7519e1151f, replyNumber=0, likeNumber=73, createdTime=2020-07-07, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7519e1151f, moduleTitle=Mol. Pharmaceutics：加拿大科学家开发新方法，可将抗癌药物**输送到肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7519e1151f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575211, encodeId=a8e415e52117b, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, objectTitle=Acta Pharmaceutica Sinica B：上海药物所开发抗新冠肺炎药物靶标预测及虚拟筛选网络应用平台, objectType=article, longId=193917, objectId=af9919391eba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9919391eba, replyNumber=0, likeNumber=73, createdTime=2020-05-12, rootId=0, userName=lfyang, userId=2c1f16064818, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9919391eba, moduleTitle=Acta Pharmaceutica Sinica B：上海药物所开发抗新冠肺炎药物靶标预测及虚拟筛选网络应用平台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9919391eba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MACE

2020-05-29

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2022-09-15

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据

2022-05-08

lfyang (审核中...)

前往app查看评论内容

#MACE#

DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关

2022-04-24

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据

2022-04-14

lfyang (审核中...)

前往app查看评论内容

#MACE#

European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？

2022-03-16

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药

2021-11-07

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药

2021-10-17

lfyang (审核中...)

前往app查看评论内容

#MACE#

武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化

2021-10-13

lfyang (审核中...)

前往app查看评论内容

#MACE#

Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响

2021-10-10

lfyang (审核中...)

前往app查看评论内容

#MACE#

Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药

2021-09-26

lfyang (审核中...)

前往app查看评论内容

#MACE#

心血管回顾性研究采用MACE作为结局哪些地方会被挑战 ?

2021-07-31

lfyang (审核中...)

前往app查看评论内容

#MACE#

Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益

2021-07-22

lfyang (审核中...)

前往app查看评论内容

#MACE#

Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！

2021-06-30

lfyang (审核中...)

前往app查看评论内容

#MACE#

Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据

2021-02-20

lfyang (审核中...)

前往app查看评论内容

#MACE#

ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒

2021-01-16

lfyang (审核中...)

前往app查看评论内容

#MACE#

Sirtex Medical和China Grand Pharmaceutical宣布SIR-Spheres Y-90树脂微球获得NMPA认可

2020-12-01

lfyang (审核中...)

前往app查看评论内容

#MACE#

Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎

2020-10-26

lfyang (审核中...)

前往app查看评论内容

#MACE#

Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持

2020-10-26

lfyang (审核中...)

前往app查看评论内容

#MACE#

Mol. Pharmaceutics：加拿大科学家开发新方法，可将抗癌药物**输送到肿瘤

2020-07-07

lfyang (审核中...)

前往app查看评论内容

#MACE#

Acta Pharmaceutica Sinica B：上海药物所开发抗新冠肺炎药物靶标预测及虚拟筛选网络应用平台

2020-05-12

科室
- - 订阅+
  - 更多科室
工具
服务